新冠病毒抗病毒药物的诊疗一体化：全球精准/个性化医学的前景与挑战

Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine.

作者信息

Manóchio Caíque, Torres-Loureiro Sabrina, Scudeler Mariana M, Miwa Bruno, Souza-Santos Fernanda C, Rodrigues-Soares Fernanda

机构信息

Departamento de Patologia, Genética e Evolução, Instituto de Ciências Biológicas e Naturais, Universidade Federal do Triângulo Mineiro, Uberaba, Brazil.

Departamento de Genética, Ecologia e Evolução, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

出版信息

OMICS. 2023 Jan;27(1):6-14. doi: 10.1089/omi.2022.0151. Epub 2023 Jan 4.

DOI:10.1089/omi.2022.0151

PMID:36602768

Abstract

Coronavirus disease 2019 (COVID-19) is a systemic disease that impacts multiple organ systems with a complex clinical presentation and outcomes that can vary from person to person and between populations. To optimize COVID-19 treatment outcomes, and in light of the availability of antiviral drugs, there is a need for greater attention to the field of theranostics, the fusion of therapeutics and diagnostics. Theranostics tests would be invaluable, we suggest in this expert review, so as to optimize the efficacy and safety of current and future antiviral drugs against COVID-19. Theranostics would also assist in the design and implementation of clinical trials with antiviral drug candidates. We discuss here theranostics considering drugs such as remdesivir, Paxlovid™, and molnupiravir. All in all, we underscore that theranostics as a concept and practice is essential for efficient and safe health interventions against COVID-19 and other ecological crises in the 21st century.

摘要

2019年冠状病毒病（COVID-19）是一种全身性疾病，会影响多个器官系统，其临床表现复杂，不同个体和人群的病情转归也存在差异。为优化COVID-19的治疗效果，鉴于抗病毒药物的可及性，有必要更加关注治疗诊断学领域，即治疗与诊断的融合。我们在这篇专家综述中指出，治疗诊断学检测将非常宝贵，有助于优化当前及未来抗COVID-19抗病毒药物的疗效和安全性。治疗诊断学还将协助设计和开展针对抗病毒候选药物的临床试验。我们在此讨论了针对瑞德西韦、帕罗韦德™和莫努匹拉韦等药物的治疗诊断学。总而言之，我们强调，治疗诊断学作为一种理念和实践，对于21世纪针对COVID-19及其他生态危机进行高效且安全的健康干预至关重要。